NADK2
Basic information
Region (hg38): 5:36192589-36242279
Previous symbols: [ "C5orf33", "NADKD1" ]
Links
Phenotypes
GenCC
Source:
- progressive encephalopathy with leukodystrophy due to DECR deficiency (Strong), mode of inheritance: AR
- progressive encephalopathy with leukodystrophy due to DECR deficiency (Moderate), mode of inheritance: AR
- progressive encephalopathy with leukodystrophy due to DECR deficiency (Supportive), mode of inheritance: AR
- progressive encephalopathy with leukodystrophy due to DECR deficiency (Limited), mode of inheritance: AR
- progressive encephalopathy with leukodystrophy due to DECR deficiency (Moderate), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
2,4-dienoyl-CoA reductase deficiency | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Biochemical; Neurologic | 24847004 |
ClinVar
This is a list of variants' phenotypes submitted to
- Progressive_encephalopathy_with_leukodystrophy_due_to_DECR_deficiency (191 variants)
- Inborn_genetic_diseases (57 variants)
- not_provided (35 variants)
- not_specified (17 variants)
- NADK2-related_disorder (7 variants)
- Bardet-Biedl_syndrome_10 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NADK2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_001085411.3. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 55 | 59 | ||||
missense | 109 | 116 | ||||
nonsense | 5 | |||||
start loss | 1 | 1 | ||||
frameshift | 5 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
Total | 0 | 2 | 119 | 58 | 7 |
Highest pathogenic variant AF is 0.0000107167
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NADK2 | protein_coding | protein_coding | ENST00000381937 | 12 | 49688 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0652 | 0.935 | 125732 | 0 | 8 | 125740 | 0.0000318 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.05 | 124 | 207 | 0.600 | 0.0000107 | 2807 |
Missense in Polyphen | 33 | 80.949 | 0.40767 | 1007 | ||
Synonymous | 0.402 | 67 | 71.3 | 0.939 | 0.00000342 | 877 |
Loss of Function | 3.37 | 7 | 25.3 | 0.277 | 0.00000137 | 306 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000909 | 0.0000905 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000367 | 0.0000352 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000677 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Mitochondrial NAD(+) kinase that phosphorylates NAD(+) to yield NADP(+). Can use both ATP or inorganic polyphosphate as the phosphoryl donor. Also has weak NADH kinase activity in vitro; however NADH kinase activity is much weaker than the NAD(+) kinase activity and may not be relevant in vivo. {ECO:0000269|PubMed:23212377}.;
- Pathway
- Nicotinate and nicotinamide metabolism - Homo sapiens (human);Metabolism;Nicotinate metabolism;Metabolism of water-soluble vitamins and cofactors;Metabolism of vitamins and cofactors
(Consensus)
Intolerance Scores
- loftool
- rvis_EVS
- 0.53
- rvis_percentile_EVS
- 80.73
Haploinsufficiency Scores
- pHI
- 0.156
- hipred
- Y
- hipred_score
- 0.673
- ghis
- 0.448
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- gene_indispensability_score
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Nadk2
- Phenotype
- liver/biliary system phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); limbs/digits/tail phenotype; immune system phenotype; homeostasis/metabolism phenotype; cellular phenotype;
Gene ontology
- Biological process
- NADP biosynthetic process;phosphorylation;NAD metabolic process
- Cellular component
- mitochondrion;mitochondrial matrix
- Molecular function
- NAD+ kinase activity;ATP binding;protein homodimerization activity